drugset
drugset / Trial / NCT06752746

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

NCT06752746 ↗

Phase 1 Recruiting 108 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.

Timeline

Start
2024-03-21
Primary completion
2025-08-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW3011 Unknown — Intravenous

Indications

acquired polycythemia vera